… of hypercholesterolemia is a synthetic statin, 3-hydroxy-3-methyl-… crystal packing [MAS02].
Depending on whether the crystal … (2:1) in an amorphous form in its early development phase I …

… formulations of statins, but drug precipitation, the packaging challenges of … thereof. Typical
preparations are suspensions of amorphous and/or crystalline particles of one or more statins …

… play a determining role in the bioavailability thereof. It is a well-… different simvastatin:glipizide
co-amorphous preparations … bonding and crystal lattice packing. Thereby making it a …

… The formation of a cocrystal can be used to convert amorphous or difficultto-crystallize
materials. Furthermore, besides toxicity and lack of efficacy, physicochemical properties are …

… , they pack loosely, which weakens the forces of attraction between molecules. The Gibb's
free energy of drug molecules in an amorphous … For instance, the co-amorphous simvastatin-…

… the key functional groups involved in the intermolecular interactions, the applications of
each category of molecular complexes, as well as the advantages and challenges thereof. This …

… by confinement in physical containers, also the surface of a … -phase amorphous systems, as
indicated by single, composition-… Single-phase mixtures of simvastatin and glipizide showed …

… that of an amorphous phase at the same composition, then that … Project, allowing comparisons
to polymorphs therein. … to conform to the packing in the amorphous phase. In accordance …

… The higher solubility of amorphous solids is due to their higher energy and … make amorphous
solids physically unstable. During manufacturing operations and/or storage amorphous …

… in a document but which may be derived thereof, as well as inventions just selected from a
… as restricted to the substance or composition when presented or packaged for the use. Art. …